{"text": ["Senate", "Finance", "Committee", "launches", "probe", "into", "AbbVie's", "tax", "practices"], "created_at": "2021-06-02 18:47:39"}
{"text": ["AbbVie's", "Rinvoq", "Shows", "Encouraging", "Long", "Term", "Safety,", "Efficacy", "In", "Rheumatoid", "Arthritis,", "Psoriatic", "Arthritis", "Patients"], "created_at": "2021-06-02 14:02:24"}
{"text": ["AbbVie", "to", "Present", "at", "the", "Goldman", "Sachs", "42nd", "Annual", "Global", "Healthcare", "Conference"], "created_at": "2021-06-02 12:30:00"}
{"text": ["Phase", "3", "Maintenance", "Results", "Show", "Patients", "with", "Crohn's", "Disease", "Receiving", "Risankizumab", "(SKYRIZI\u00ae)", "Achieved", "Endoscopic", "Response", "and", "Clinical", "Remission", "at", "One", "Year"], "created_at": "2021-06-02 12:00:00"}
{"text": ["AbbVie", "to", "Present", "Analysis", "Evaluating", "Continuous", "RINVOQ\u00ae", "(upadacitinib)", "Treatment", "in", "Psoriatic", "Arthritis", "for", "More", "Than", "One", "Year", "at", "EULAR", "2021", "Virtual", "Congress"], "created_at": "2021-06-02 11:30:00"}
{"text": ["AbbVie", "Faces", "U.S.", "Senate", "Pressure", "Over", "Tax", "Payments"], "created_at": "2021-06-02 11:24:00"}
{"text": ["New", "Long-Term", "Efficacy", "and", "Safety", "Analyses", "Evaluating", "RINVOQ\u00ae", "(upadacitinib)", "in", "Patients", "with", "Rheumatoid", "Arthritis", "to", "be", "Presented", "at", "EULAR", "2021", "Virtual", "Congress"], "created_at": "2021-06-02 11:00:00"}
{"text": ["15", "Most", "Valuable", "Pharmaceutical", "Companies", "In", "The", "World"], "created_at": "2021-06-02 05:44:25"}
